Company news: Merck, Affymax, AstraZeneca

Deborah Weinstein

March 28 2012

Merck said Wednesday that its big outcomes study of cholesterol drugs Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin) will be extended.

Your Name: *

Your Email Address: *

Recipient(s) Email Address: *

(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)

Subject:*

Your message:

Send Me A Copy

The e-mail address(es) that you supply to use this service will only be used to send the requested article.